This application for a Specialized Program of Research Excellence in Gastrointestinal (Pancreatic Cancer) will focus on translational studies that address basic and clinical issues of importance to improving the outcome of patients with pancreatic cancer. Specifically, the research projects in this program seek to: 1) develop and test novel diagnostic reagents and assays that will improve our ability to detect pancreatic cancer in its early stages;2) develop and test novel therapeutic strategies including immunotherapy, chemotherapy, and chemoradiation therapy for patients with early and advanced pancreatic cancer;3) undertake basic research studies in conjunction with clinical trials that will provide insight at the molecular level into the reasons for success and failure of the different strategies. The proposed SPORE program is focused on 4 projects with the high potential translational impact, and there are 2 highly interactive cores that will continue to acquire, store, and make available a unique set of tissue samples, data (clinical, molecular genetic, biological, pathological), reagents and resources: Project 1: Immunotherapy of Pancreatic Adenocarcinoma Project 2: Inhibitors of N-cadherin in the treatment of pancreatic cancer. Project 3: Biological marker(s) in the diagnosis of pancreatic cancer Project 4: Inhibitors of Telomerase in treatment of pancreatic adenocarcinoma Core 1: Administration Core 2: Pancreas Tumor SPORE Tissue Bank Core 3: Biostatistics

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA127297-05
Application #
8328177
Study Section
Special Emphasis Panel (ZCA1-GRB-I (M1))
Program Officer
Agarwal, Rajeev K
Project Start
2008-09-05
Project End
2014-08-31
Budget Start
2012-09-01
Budget End
2014-08-31
Support Year
5
Fiscal Year
2012
Total Cost
$1,066,666
Indirect Cost
$309,561
Name
University of Nebraska Medical Center
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
168559177
City
Omaha
State
NE
Country
United States
Zip Code
68198
Krasnoslobodtsev, Alexey V; Torres, MarĂ­a P; Kaur, Sukhwinder et al. (2015) Nano-immunoassay with improved performance for detection of cancer biomarkers. Nanomedicine 11:167-73
Kaur, Sukhwinder; Sharma, Neil; Krishn, Shiv Ram et al. (2014) MUC4-mediated regulation of acute phase protein lipocalin 2 through HER2/AKT/NF-*B signaling in pancreatic cancer. Clin Cancer Res 20:688-700
Liu, Xiang; Yi, Chunhui; Wen, Yunfei et al. (2014) Interactions between MUC1 and p120 catenin regulate dynamic features of cell adhesion, motility, and metastasis. Cancer Res 74:1609-20
Momi, Navneet; Kaur, Sukhwinder; Rachagani, Satyanarayana et al. (2014) Smoking and microRNA dysregulation: a cancerous combination. Trends Mol Med 20:36-47
Kane, Daniel P; Shcherbakova, Polina V (2014) A common cancer-associated DNA polymerase ? mutation causes an exceptionally strong mutator phenotype, indicating fidelity defects distinct from loss of proofreading. Cancer Res 74:1895-901
Stark, Jaime L; Mehla, Kamiya; Chaika, Nina et al. (2014) Structure and function of human DnaJ homologue subfamily a member 1 (DNAJA1) and its relationship to pancreatic cancer. Biochemistry 53:1360-72
Mehla, Kamiya; Singh, Pankaj K (2014) MUC1: a novel metabolic master regulator. Biochim Biophys Acta 1845:126-35
Mimeault, Murielle; Batra, Surinder K (2014) Molecular biomarkers of cancer stem/progenitor cells associated with progression, metastases, and treatment resistance of aggressive cancers. Cancer Epidemiol Biomarkers Prev 23:234-54
Kaur, Sukhwinder; Momi, Navneet; Chakraborty, Subhankar et al. (2014) Altered expression of transmembrane mucins, MUC1 and MUC4, in bladder cancer: pathological implications in diagnosis. PLoS One 9:e92742
Dey, Parama; Rachagani, Satyanarayana; Vaz, Arokia P et al. (2014) PD2/Paf1 depletion in pancreatic acinar cells promotes acinar-to-ductal metaplasia. Oncotarget 5:4480-91

Showing the most recent 10 out of 73 publications